



UNIVERSITY OF LEEDS

This is a repository copy of *Drug-free inactive disease in juvenile idiopathic arthritis can be achieved for 40% of patients.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/149679/>

Version: Accepted Version

Article:

Chapman, L and Friend, AJ orcid.org/0000-0001-9864-5605 (2020) Drug-free inactive disease in juvenile idiopathic arthritis can be achieved for 40% of patients. Archives of Disease in Childhood.education and Practice Edition, 105 (1). p. 64. ISSN 1743-0585

<https://doi.org/10.1136/archdischild-2019-317833>

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. This is an author produced version of a abstract published in Archives of Disease in Childhood.education and Practice Edition. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Drug-free inactive disease in Juvenile Idiopathic Arthritis can be achieved for 40% of patients

Study Design: Randomised, single-blind trial

Study Question

Setting: The Netherlands

Patients: 94 patients with new-onset (symptom duration <18 months) JIA who had not been exposed to previous disease-modifying anti-rheumatic drug (DMARD) therapy.

Interventions: Conventional systemic (cs) DMARD monotherapy (methotrexate (MTX) or sulfasalazine) vs MTX plus 6 week tapered course of prednisolone vs MTX plus etanercept.

Outcomes: Time to inactive disease (TID); time to flare (TTF) after first episode of drug-free inactive disease (DFID).

Main Results:

The main study outcomes are summarised in table 1.

Outcomes	csDMARD (n=32)	MTX plus prednisolone (n=32)	MTX plus etanercept (n=30)
Median TID (months)	9 (5.3-15.0)	9 (6.0-12.0)	9 (6.0-12.0)
Median TTF (months)	4.5 (3.0-9.0)	3.0 (3.0-3.0)	3.0 (3.0-7.5)
Inactive disease after 24 months	71%	70%	72%
DFID after 24 months	45%	31%	41%

Table 1: Summary of TID, required drug changes and sustained DFID in each treatment arm.

CONCLUSION:

Despite small numbers, there did not appear to be any significant difference between treatment modalities when achieving inactive disease. DFID was shown to be an achievable target for a significant minority of patients with new-onset JIA.

ABSTRACTED FROM: Hissink, P.M., Brinkman, D.M.C., Schonenberg-Meinema, D., Koopman-Keemink, Y., Brederije, I.C.J., Bekkering, P.W., Kuijpers, T.W., Van, M.R., Boehringer, S., Allaart, C.F. and Ten, R.C., 2019. Treat to target (drug-free) inactive disease in DMARD-naïve juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial. *Annals of the rheumatic diseases*, 78(1), pp.51-59.

Abstracted by Laura Chapman, Faculty of Medicine and Health,
University of Leeds, Leeds, England, laura-chapman@live.co.uk.

Commentary: Inactive disease in JIA has long been considered a realistic goal, due to the availability of effective pharmacological therapies (1). This study goes one step further, and explores the possibility of maintaining inactive disease following cessation of medications.

This study is too small to draw any firm conclusion about the equivalence of the three treatment strategies, but intriguingly suggests the speed of improvement and rate of drug free remission are similar across agents. Previous studies have suggested that newer biological therapies may be more effective at inducing disease remission than conventional anti-rheumatic therapies (2). This finding requires further study. The long-term use of corticosteroid treatment in paediatric rheumatological disease is associated with significant morbidity (3), and treating clinicians often aim to use alternative therapies in order to reduce the requirement for steroid treatment. However, there has been less drive to discontinue the so-called "steroid-sparing" agents.

Whilst a single study of this size is unlikely to result in a change of practice for most paediatricians, it does remind us that medication cessation is a reasonable goal once clinical remission has been obtained.

1. Sengler, C., 2019. New therapy approaches, better outcomes?: Results from inception cohorts for patients with juvenile idiopathic arthritis. *Zeitschrift fur Rheumatologie*.
2. Tynjälä, P., Vähäsalo, P., Tarkiainen, M., Kröger, L., Aalto, K., Malin, M., Putto-Laurila, A., Honkanen, V. and Lahdenne, P., 2011. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. *Annals of the rheumatic diseases*, 70(9), pp.1605-1612.
3. Heshin-Bekenstein, M., Trupin, L., Yelin, E., von Scheven, E., Yazdany, J. and Lawson, E.F., 2019, June. Longitudinal Disease-and Steroid-Related Damage Among Adults with Childhood-Onset Systemic Lupus Erythematosus. *Seminars in Arthritis and Rheumatism*. epub ahead of print